Blog

 Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it has expanded its patent portfolio through the filing of international patents in Canada, the United States, Europe and Australia for Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder. ‘This important step is a significant demonstration of our capabilities, particularly as we expand our footprint globally through conducting controlled clinical trials with our patent-pending compound and expanding our patent portfolio internationally. Specifically with…

The Stock Day Podcast welcomed PSYC Corporation (PSYC), integrating media, creativity, and technology to develop and deploy thought-provoking ideas and solutions that are fostering and transforming the approach to some of society’s most pressing matters. CEO of the Company, David Flores, joined Stock Day host Everett Jolly. “PSYC Corporation, through our wholly-owned subsidiary Spotlight Media Corp., has become a multimedia leader for forward thinking industries, which is really dialed in on the psychedelic, cannabis, and now mining and precious metals sectors.” David Flores, CEO Jolly then asked about the Company’s recently announced media asset purchases, including Technical420.com and Mushroomstocks.com. “The…

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) has reached a binding agreement on September 30, 2022 to acquire Ketamine Infusions of Idaho, PLLC, which operates a clinic in Idaho Falls. The clinic will join Irwin Naturals Emergence, a fast-growing national chain of psychedelic mental-health clinics, which already has deals to add a total of 11 clinics across six different states. This clinic will be the chain’s first in Idaho. “We are so impressed by the care and expertise that Christina Stubbs and her team provide, and we are truly excited to welcome this clinic into our rapidly expanding family. Additions like this are the way…

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the initiation of a Phase 1 investigator-initiated trial led by MindMed collaborator Prof. Dr. Matthias Liechti at University Hospital Basel (UHB). The study aims to compare acute responses to R-MDMA, S-MDMA, and MDMA in healthy subjects. “MDMA is a racemic substance containing equal amounts of the enantiomers S-MDMA and R-MDMA. Preclinical research indicates that S-MDMA mainly releases dopamine, norepinephrine, serotonin, and oxytocin while R-MDMA may act more directly on 5-HT2A receptors and release prolactin. Animal studies indicate that R-MDMA…

Host Margaret Williamson is back with another opportunity to shift your mind. This time around, she’s joined by Olivia Mannix, the Founder, and CEO of Felicity Pharma. Meet Olivia Mannix Olivia is an award-winning entrepreneur and cannabis & psychedelics business pioneer. Olivia is the intuitive leader of marketing and the business revolution. She founded one of the first ancillary cannabis companies, Cannabrand in 2013. Being the innovator behind the movement to destigmatize cannabis and psychedelics, she recognized these opportunities long before they were widely accepted. She has founded several other companies including a tech SaS platform and sales application. She…